Rationale: Pre-exposure prophylaxis is a strategy that aims to use antiretrovirals to reduce the risk of HIV infection. Studies in non-human primates have shown that both oral and topical applications of ARVs before exposure reduce risk or completely prevent infection with challenge by an HIV-like virus that causes disease in monkeys.
TDF (marketed under the name Viread) is an antiretroviral used by HIV-positive people as part of highly active antiretroviral therapy.
Study question(s): This study is designed to examine the safety and efficacy of a PrEP strategy (once-daily tenofovir) in injection drug users. The trial is designed to examine whether regular use of tenofovir is safe and whether it reduces the risk of HIV infection in people whose primary risk factor is injection drug use.
Participants: 2,400 HIV-negative injecting drug users (IDUs)
Country: Thailand (Bangkok)
Trial sponsors and collaborators: US Centers for Disease Control and Prevention (CDC)
When can we expect results? 2012
To learn more visit:
http://www.cdc.gov/hiv/resources/factsheets/prep.htm
http://clinicaltrials.gov/ct2/show/NCT00119106?term=CDC+4370&rank=1